AbbVie (ABBV) Long-Term Deferred Tax (2013)

AbbVie (ABBV) reported Long-Term Deferred Tax of -$582.0 million for Q3 2013.

AbbVie (ABBV) Long-Term Deferred Tax (2013) Analysis & Trends

AbbVie (ABBV) has 1 years of Long-Term Deferred Tax data on file, last reported at -$582.0 million in Q3 2013.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Gsk	92,316,836.42 Bn	92,316,831.46 Bn	7.76 Bn
2	Eli Lilly	983.57 Bn	978.29 Bn	16.22 Bn
3	Johnson & Johnson	553.56 Bn	531.50 Bn	15.96 Bn
4	AbbVie	383.35 Bn	374.00 Bn	10.78 Bn
5	Merck	281.71 Bn	276.06 Bn	12.09 Bn
6	Amgen	182.20 Bn	170.16 Bn	5.87 Bn
7	Gilead Sciences	153.71 Bn	145.98 Bn	5.52 Bn
8	Pfizer	143.75 Bn	130.98 Bn	-1.21 Bn
9	Bristol Myers Squibb	109.71 Bn	99.25 Bn	8.07 Bn
10	Novartis Ag	108.28 Bn	107.60 Bn	-

Download Data

Date	Value
Sep 30, 2013	-582.00 Mn